Drug Abuse Warning Network (DAWN): ED Visits Involving Alcohol Short Report presents the following data from January 2021-September 2023 (1) national estimates and characteristics of alcohol-related ED visits (2) demographics of alcohol-related ED visits (3) percent of ED visits related to alcohol and at least one other substance.

The third supplemental to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. A compendium of resources for professionals who work with parents involved with child welfare.

The second supplemental to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. This document contains information for pregnant people with a substance use disorder and professionals who provide services for them.

This document accompanies the Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. It offers information about child welfare systems and what the health care provider's role is in developing a Plan of Safe Care.

This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.

The N‑SUMHSS is a voluntary annual survey of all active substance use and mental health facilities in the United States, its territories, and D.C. The annual report presents findings on the general profile of substance use and mental health facilities, use of pharmacotherapies/medications, language assistance provided, and suicide prevention services.

This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.

This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).

This user guide provides a digestible overview of the Report to Congress for prevention professionals, state and local agencies, and community-based organizations.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.